Showing results (11-20 of 377) with videos related to
Sort By:
Pageof 38
Blood|August 15, 2000
Immunity to WT1 in the animal model and in patients with acute myeloid leukemiaA Gaiger, V Reese, M L Disis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 1999
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccineM L Disis, K H Grabstein, P R Sleath, et al.Annals of the New York Academy of Sciences|August 12, 1993
T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-ablM A Cheever, W Chen, M L Disis, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|August 1, 1993
Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic proteinD J Peace, J W Smith, M L Disis, et al.Cancer Research|February 15, 1994
In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene proteinM L Disis, J W Smith, A E Murphy, et al.Human Immunology|February 1, 1997
Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8J Lustgarten, M Theobald, C Labadie, et al.Archives of Otolaryngology--Head & Neck Surgery|February 1, 1995
Serum immunoglobulins specific for intracellular proteins of squamous cell carcinomaE Calenoff, M A Cheever, M Satam, et al.Cancer Research|January 1, 1994
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancerM L Disis, E Calenoff, G McLaughlin, et al.Current Oncology Reports|October 12, 2001
The role of bisphosphonates as adjuvant therapy for breast cancerJ R GralowEndocrine-Related Cancer|March 27, 2002
Vaccination against the HER-2/neu oncogenic proteinH Bernhard, L Salazar, K Schiffman, et al.Pageof 38